CGTX Projected Dividend Yield
Cognition Therapeutics Inc ( NASDAQ : CGTX )Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina. Its lead candidate, CT1812, is being investigated for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration (dry AMD). CT1812 is an orally delivered modulator that crosses the blood-brain and blood-retina barriers, selectively binding to the sigma-2 receptor (S2R) complex. This modulation restores normal synapse function and critical cellular processes like autophagy, cholesterol biosynthesis, and vesicle trafficking. 21 YEAR PERFORMANCE RESULTS |
CGTX Dividend History Detail CGTX Dividend News CGTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |